Method for treating hypocalcemia, osteoporosis , fractures

FIELD: medicine, orthopedics.

SUBSTANCE: the present innovation deals with treating osseous diseases caused by calcium exchange disorders. For this purpose certain calcium preparations should be reduced up to amorphous state to be perorally applied per 0.5-1.0 g, 2-4 times daily, at courses of not less than 10 d. The innovation provides efficient treatment due to high biodigestibility of amorphous calcium and its active accumulation in bony tissue.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

 

The invention relates to medicine, in particular highly conservative treatment hypocalcaemia, osteoporosis of various Genesis, osteomyelitis, bone cysts, osteochondrosis, osteochondropathy, fractures and pathological fractures of the limbs, etc.

There is a method of treatment of hypocalcaemia, including intravenous liquid-official 5-10% dosage forms of calcium (CA) (Traumatology and Orthopaedics, edited Ugudapotov, M.: Medicine, 1997, part 3, pp.69-91).

The disadvantages of this method are invasive method of administration of drugs, rapid elimination from the blood and, as a consequence, lack of effectiveness.

Known another method of treating hypocalcaemia and osteoporosis of various Genesis, including oral preformed solid crystalline forms of drugs calcium gluconate (Volkov M.V. bone Diseases in children, 2nd ed., M.: Medicine, 1985, 512 S.).

The disadvantages of this method, taken as a prototype, is low biouswoyaemosti organism used dosage forms, the need for surgical intervention, restoration or replacement of bone tissue and, in General, low efficiency.

The objective of the invention is to provide a method that will allow efficient con is ervative treatment of hypocalcaemia, osteoporosis of various Genesis, osteomyelitis, bone cysts, osteochondrosis, osteochondropathy, pathological fractures, fractures, etc. without exposing patients to surgery, to eliminate the defects of bone tissue without their prosthesis or replacement.

The problem is solved because, according to the method of treatment of hypocalcaemia, osteoporosis, fractures involving the use of calcium supplementation official dispersed solid crystalline or preformed crystalline drugs calcium pre-ground to the amorphous state, administer orally, 2-4 times a day, with doses of 0.5-1.0 grams, courses for 15-20 days with interruptions in the use of 1-2 weeks until full recovery. Calcium supplements is crushed to particle size not exceeding 1 micron.

Advantages of the method lie in the possibilities highly conservative treatment hypocalcaemia, osteoporosis of various Genesis, osteomyelitis, bone cysts, osteochondrosis, osteochondropathy, fractures and pathological fractures of the limbs, etc. due to increased biological activity of amorphous nanoscale particles of calcium supplementation significantly due to the increased chemical reactivity of metastable amortiziruemoe status and degree of surface. The proposed pic is b treatment gives a steady guaranteed a positive result, does not require surgery, eliminates the defects of bone tissue without their prosthesis or replacement at the expense of improving biostatement applied mechanically activated calcium supplements.

The method is implemented as follows. Pre grinding devices spend grinding famous official dispersed solid crystalline or preformed crystalline drug calcium. The treatment is carried out by energonapryazhennosti the 0.4 to 50.0 kJ/g are Thus obtained mechanochemically activated form of the drug calcium in amorphous state with a particle size not exceeding 1 micron. Amorphous state and nanometer size particles in the range of 50-300 nm provide high biouswoyaemosti drug. Obtained mechanochemically activated form of the drug calcium for the treatment of hypocalcaemia, osteoporosis, fractures of various origins is applied orally, 2-4 times a day, with doses of 0.5-1.0 grams, courses for 15-20 days with interruptions in the use of 1-2 weeks until full recovery.

Examples of specific implementation of the method.

Example 1. Patient A. 14 years. Diagnosis: systemic juvenile osteopenia, hypocalcemia, pain syndrome. For treatment was applied powdered calcium gluconate amorphous state with a particle size of 50-300 nm. The course of the yen 6-month course of treatment by the proposed method. Calcium content in the blood serum of normal and the pain disappeared.

Example 2. Patient B. 12 years. The diagnosis of a cyst of the distal metaphysis of tubular bones, the pain syndrome. For treatment was applied powdered calcium gluconate amorphous state with a particle size of 50-300 nm. Conducted an 8-month course of treatment by the proposed method. The bone defect was filled with a structural bone pain disappeared. The suspect removed a question about the need for surgery.

1. A method of treating hypocalcaemia, osteoporosis, fractures involving the use of calcium supplements, characterized in that the official dispersed solid crystalline or preformed crystalline drugs calcium pre-ground to the amorphous state and is used orally 2-4 times a day in doses of 0.5-1.0 g, courses not less than 10 days.

2. The method of treatment according to claim 1, characterized in that the calcium is crushed to a particle size not exceeding 1 micron.



 

Same patents:

FIELD: medicine; medical engineering.

SUBSTANCE: biotransplant has genetically unmodified mesenchyma stem cell culture as active component obtained from fetal donor autologous material. The tissue is subjected to disaggregation and the produced cell suspension is resuspended and cultivated on growth medium containing transferrin, insulin, fibroblast growth factor and heparin to accumulate mature stroma in cell culture. Method involves intravenously dropping mesenchyma stem cell culture in the amount of 50 to 500 mln in 50-100 ml of physiologic saline.

EFFECT: accelerated recovery of bone tissue; positive biochemical factors dynamics; improved patient locomotor activity.

6 cl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel substituted 2-aryl-3-(heteroaryl)imidazo[1,2-a]-pyrimidines of the formula (I):

or to their pharmaceutically acceptable salts wherein: (a) R1 is taken among the group consisting of -NH2, C1-5-alkylamino-, di-C1-5-alkylamino-, phenylmethylamino-group; (b) Y is taken among the group consisting of hydrogen atom (H), halogen atom, piperidine, OR4, SR4, -SO2CH3, NHR4 and NR4R5 wherein R4 and R5 are taken independently among hydrogen atom (H), α-alkylphenyl-C1-5-alkyl, linear or branched alkyl substituted optionally with C3-5-carbocycle, phenyl or substituted phenyl wherein indicated phenyl can be substituted with one or some substituted taken among C1-5-alkoxy-group; (c) R2 represents from one to five members taken independently among the group including hydrogen atom (H), halogen atom, trifluoromethyl; (d) R3 represents hydrogen atom (H), or radicals R3 taken in common form aromatic ring; (e) X represents nitrogen atom (N) or -CH. Also, invention relates to methods for preparing indicated compounds and to a method for treatment based on these compounds. Invention provides preparing novel compounds that can be used in relief states by reducing the level of inflammatory cytokines, for example, the indicated state represents proliferative (rheumatic) arthritis.

EFFECT: valuable medicinal properties of compounds and compositions.

40 cl, 1 tbl, 4 ex

FIELD: medicine, phytotherapy, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to using Belamcanda chinensis extract for preparing organ-selective medicinal preparation without uterotropic effect or with minimal such effect that is used as estrogen-like preparation. This preparation is used in selective treatment and/or prophylaxis of cardiovascular diseases, in particular, atherosclerosis and osteoporosis, climacteric disturbances, especially for prophylaxis or softening congestions of blood. Extract is used in manufacturing a medicinal preparation in ready formulation for selective treatment and/or prophylaxis of cardiovascular diseases, in particular atherosclerosis, and for selective treatment and/or prophylaxis of osteoporosis, climacteric disturbances, especially for prophylaxis and softening congestions of blood. Extract promotes to effective prophylaxis and/or treatment of cardiovascular diseases, in particular, atherosclerosis, climacteric disturbances, especially for prophylaxis and softening congestions of blood.

EFFECT: valuable medicinal properties of extract.

4 cl, 4 ex

FIELD: organic chemistry, vitamins, medicine, pharmacy.

SUBSTANCE: invention relates to a new compound of the formula (I): wherein X means hydrogen atom or hydroxy group; R1 and R2 that can be similar or different mean hydrogen atom, (C1-C4)-alkyl; R3 means hydrogen atom, methyl group, fluorine or chlorine atom. Also, invention relates to its esters able to hydrolysis in vivo in combination with pharmaceutically acceptable acids. Also, invention relates to a pharmaceutical composition eliciting the inhibitory activity with respect to proliferation and promoting differentiation of cells and comprising the effective dose of compound of the formula (I) in common with pharmaceutically acceptable carriers and/or excipients. Also, invention relates to applying compound of the formula (I) for preparing a medicine used in treatment and prophylaxis of disease characterizing by abnormal differentiation of cells and/or proliferation of cells.

EFFECT: valuable medicinal properties of compounds.

13 cl, 3 sch, 3 tbl, 6 ex

FIELD: medicine, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to new applying EP4 receptors agonist for treatment and/or prophylaxis of diseases associated with loss of osseous mass. Agonists of EP4 receptors show high effectiveness in treatment of diseases associated with loss of osseous mass, among the, as osteoporosis of different genesis. Agonists of EP4 receptors involve prostaglandin skeleton base.

EFFECT: valuable medicinal properties of pharmaceutical composition.

16 cl, 3 tbl, 5 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of indol-3-yl of the formula (I):

wherein each A and B represents independently of one another oxygen atom (O), NH, CONH, NHCO or a direct bond; X means (C1-C2)-alkylene or a direct bond; R1 means hydrogen atom (H); R2 means hydrogen atom (H); R3 means NHR6, -NR6-C(=NR6)-NHR6, -C(=NR6)-NHR6, -NR6-C(=NR9)-NHR6, -C(=NR9)-NHR6 or Het1; each R4 and R5 represents independently of one another hydrogen atom (H); R7 means -(CH2)o-Ar, Het, OR6; R6 means hydrogen atom (H); R7 means (C1-C10)-alkyl, (C3-C10)-cycloalkyl; R8 means Hal, NO2 (nitro-group), CN (cyano-group), Z, -(CH2)o-Ar, COOR1, OR1, CF3, OCF3, NHR1; R9 means CN or NO2; Z means (C1-C6)-alkyl; Ar means aryl that can represent unsubstituted, monosubstituted, or polysubstituted R8; Hal means F, Cl, Br, J; Het means saturated, partially or completely saturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members wherein 1 or 2 nitrogen atom (N) and/or 1 or two sulfur atom (S) present, and heterocyclic radical can be monosubstituted with phenyl; Het1 means saturated, partially or completely unsaturated monocyclic or bicyclic heterocyclic radical comprising from 5 to 10 ring members and from 1 to 4 nitrogen atoms (N) that can be unsubstituted or monosubstituted NHX, or oxo-group; n = 0, 1 or 2; m = 0, 1, 2, 3, 4, 5 or 6; o means 0, 1 or 2; and their physiologically acceptable salts and solvates. Compounds of the formula (I) elicit intergin-inhibitory effect that allows their using as components of pharmaceutical composition. Also, invention describes intermediate compounds.

EFFECT: valuable medicinal properties of compounds.

11 cl, 4 sch, 1 tbl, 34 ex

FIELD: medicine.

SUBSTANCE: on should apply the suggested compound of formula 1 for treating and/or preventing osteoporosis and related osseous diseases.

EFFECT: higher efficiency of therapy and prophylaxis.

7 cl, 2 dwg, 21 ex, 6 tbl

FIELD: organic synthesis.

SUBSTANCE: invention provides compounds of general formula I:

in which R1 represents H, halogen, OCH3, or OH; R2 represents (a) -X-(CH2)n-CH2-N(R4)R5, where (i) X represents NH or S; n is integer from 1 to 4; R4 and R5, the same or different, represent C1-C4-alkyl, H, -CH2C≡CH, or -CH2CH2OH; or R4 and R5, together, form nitrogen-containing five- or six-membered cycle or heteroaromatic cycle; or where (ii) X represents O; n is integer from 1 to 4; one of R4 and R5 is CH2C≡CH, or -CH2CH2OH and the other H or C1-C4-alkyl; or R4 and R5, together, form imidazole cycle or nitrogen-containing six-membered cycle or heteroaromatic cycle; or R2 represents (b) -Y-(CH2)nCH2-O-R5, where (i) Y represents O; n is integer from 1 to 4; and R6 represents -CH2CH2OH or -CH2CH2Cl; or where (ii) Y represents NH or S; n is integer from 1 to 4; and R6 represents H, -CH2CH2OH, or -CH2CH2Cl; or R2 represents (c) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, or 2,2-diethyl-2-hydroxy-ethoxy; R3 represents H. halogen, OH, or -OCH3. Claimed compounds are novel selective estrogen receptor modulators. Invention also discloses pharmaceutical composition and a method for production of tissue-specific estrogenic and/or antiestrogenic effect in patient, for whom indicated effect is required.

EFFECT: increased choice of estrogen receptor modulators.

19 cl, 7 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: method involves administering selective modulator of steroid sex hormones being in particular compounds of general formula(I) and some quantity of steroid sex hormones precursor selected from a group composed from dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-en-3β,17β-diol and compounds in vivo transformable into one of cited precursors. Bisphosphonates combined with selective estrogen receptor modulators and/or steroid sex hormones precursor are additionally introduced for medically treating and/or inhibiting osteoporosis progress.

EFFECT: enhanced effectiveness of treatment; excluded adverse side effects.

41 cl, 13 dwg, 4 tbl

FIELD: medicine, therapy.

SUBSTANCE: simultaneously for 20 d one should prescribe calcium D3 two times daily in the morning and in the evening per 1 tablet or Beresh Plus drops. The quantity of drops for daily intake is equal to patients body weight in kg and they should be introduced in three stages during meals by drinking them up with sufficient amount of water. Application of the suggested method optimizes calcium exchange in patients with osteoporosis, enables to achieve earlier and more stable results in normalization of calcium content in bones by preventing, thus, osteoporotic fractures.

EFFECT: higher efficiency of pharmacological correction.

1 ex

FIELD: medicine, narcology.

SUBSTANCE: method involves alternating comatose therapy and electroshock therapy every other day. In day carrying out the comatose therapy eserine ointment is placed in conjunctival sacs to patient and in 30 min 2-2.5 mg scopolamine hydrobromide solution is administrated as its 0.5% solution. Then in 3-5 h of comatose state patient is recovered from coma and 15-30 mg of physostigmine, 6 g of pyracetam, 7.5 g of magnesium sulfate and 400 ml of sodium hypochlorite are administrated by intravenous drops. In each next séance of comatose therapy dose of scopolamine hydrobromide is increased by 0.5 mg and brought about to 5-6 mg. In day carrying out electroshock therapy 1 ml of 0.1% solution of atropine sulfate and 2 ml of cordiamine are administrated and preliminary narcosis is carried out by intravenous administration of 200-300 mg of sodium thiopental or 100 mg of ketamine with simultaneous administration of 3-4 ml 2% ditiline solution and electroshock therapy is carried out followed by artificial lungs ventilation. Method provides enhancing effectiveness of treatment and to prolong the remission period.

EFFECT: enhanced effectiveness of treatment.

3 ex

FIELD: medicine.

SUBSTANCE: means comprises amber acid and/or its salts, fructose, dry extraction of Saint John's wort, magnesium ion sources, potassium ion sources as active bases and auxiliary substances, carriers and/or fillers when needed.

EFFECT: enhanced effectiveness of treatment.

4 cl, 4 tbl

FIELD: veterinary science.

SUBSTANCE: the suggested preparation for preventing and treating foot rot in animals includes the product of mustard seeds processing - allyl mustard oil and an emulsifier - an aqueous bischofite solution of natural mineral at the following ratio of components, weight%: allyl mustard oil 0.01-1.0, bischofite 2.0-20.0, water - the rest. The suggested composition is highly efficient and provides improved curative effect after 5-10 foot baths in animals.

EFFECT: higher efficiency.

2 ex

FIELD: medicine.

SUBSTANCE: material comprises synthesized material having hydroxyapatite structure and additional ytterbium and erbium ions or ytterbium and thulium ions according to known formula. The material is compositionally equivalent to human skeletal bone tissue and biocompatible with it.

EFFECT: wide range of use in investigating tissue behavior in different fields of surgery and traumatic surgery.

The invention relates to medicine, namely to multicomponent infusion solutions with detoxification, hepatoprotective effect, and can be used in the intoxication of the organism of various severity
The invention relates to the field of pharmaceutical industry and relates to a medicinal product for the treatment of diseases of musculoskeletal system

The invention relates to medicine, in particular to the gynecologist, and for the treatment of secondary hypoestrogyny women

Complex drug // 2228184
The invention relates to the field of medicine
The invention relates to medicine and can be used in the treatment of infectious diseases in children
The invention relates to medicine, namely to addiction

FIELD: medicine.

SUBSTANCE: material comprises synthesized material having hydroxyapatite structure and additional ytterbium and erbium ions or ytterbium and thulium ions according to known formula. The material is compositionally equivalent to human skeletal bone tissue and biocompatible with it.

EFFECT: wide range of use in investigating tissue behavior in different fields of surgery and traumatic surgery.

Up!